FDA approves TherMatrx' microwave BPH (benign prostatic hyperplasia) therapy:
This article was originally published in Clinica
Executive Summary
The US FDA has approved for sale TherMatrx' TMx-2000 transurethral microwave thermotherapy device for benign prostatic hyperplasia (BPH). Results from a three-year, 200-patient trial of the device showed that it achieved highly significant improvements in patient symptoms, with minimal side effects. TherMatrx is based in Chicago, Illinois.
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.